Remissão de Tiques Vocais e Controle de Tiques Motores em Síndrome de Tourette Pediátrica com Tratamento Exclusivo de Extratos de Cannabis sativa L.: Relato de Caso
DOI:
https://doi.org/10.64597/72v2pe54Palavras-chave:
Síndrome de Tourette, Cannabis sativa L., Canabidiol , Tetraidrocanabinol, Sistema EndocanabinoideResumo
A Síndrome de Tourette (ST) é um transtorno neuropsiquiátrico crônico, caracterizado por tiques motores e vocais, cujo tratamento convencional frequentemente se mostra insuficiente ou associado a efeitos adversos. Este estudo de caso tem como objetivo relatar a resposta terapêutica de um paciente de 11 anos com ST, submetido ao tratamento com extratos de Cannabis sativa L.. O paciente apresentava um quadro severo (YGTSS de 50/100), e a abordagem inicial com periciazina e fluoxetina resultou em controle insatisfatório e efeitos colaterais. Após o diagnóstico definitivo, o paciente iniciou o tratamento adjuvante com extratos full spectrum de Cannabis sativa L. (THC 3,75 mg/noite e CBD 11,25 mg/dia). Observou-se melhora na qualidade do sono e estabilidade emocional, com redução da intensidade e frequência dos tiques. A boa resposta clínica permitiu a retirada gradual da fluoxetina, mantendo o tratamento exclusivo com os extratos canabinoides. O paciente alcançou remissão completa dos tiques vocais e persistência de tiques motores leves, sem impacto funcional relevante. No follow-up, a gravidade geral dos tiques reduziu significativamente para 13/100 (redução de 74% na gravidade percebida). O acompanhamento multiprofissional foi crucial para otimizar os resultados. Este caso sugere o potencial dos extratos de Cannabis sativa L. como uma alternativa terapêutica segura e eficaz para ST, especialmente em pacientes com resposta inadequada aos tratamentos tradicionais.
Referências
1. Robertson M, Eapen V, Singer H, Martino D, Scharf J, Paschou P, et al. Gilles de la Tourette syndrome. Nat Rev Dis Primers. 2017;3:16097. DOI: https://doi.org/10.1038/nrdp.2016.97
2. Knight T, Steeves T, Day L, Lowerison M, Jette N, Pringsheim T. Prevalence of tic disorders: A systematic review and meta-analysis. Pediatr Neurol. 2012;47(2):77–90. DOI: https://doi.org/10.1016/j.pediatrneurol.2012.05.002
3. Jafari F, Abbasi P, Rahmati M, Hodhodi T, Kazeminia M. Systematic review and meta-analysis of Tourette syndrome prevalence; 1986 to 2022. Pediatr Neurol. 2022;137:6–16. DOI: https://doi.org/10.1016/j.pediatrneurol.2022.08.010
4. Chadehumbe MA, Brown LW. Advances in the treatment of Tourette’s disorder. Curr Psychiatry Rep. 2019;21(5):31. DOI: https://doi.org/10.1007/s11920-019-1018-z
5. Leckman JF, Bloch MH, Smith ME, Larabi D, Hampson M. Neurobiological substrates of Tourette’s disorder. J Child Adolesc Psychopharmacol. 2010;20(4):237–47. DOI: https://doi.org/10.1089/cap.2009.0118
6. Pringsheim T, Okun MS, Müller-Vahl K, Martino D, Jankovic J, Cavanna AE, et al. Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology. 2019;92(19):896–906. DOI: https://doi.org/10.1212/WNL.0000000000007466
7. Seideman MF, Seideman TA. A review of the current treatment of Tourette syndrome. J Pediatr Pharmacol Ther. 2020;25(5):401–12. DOI: https://doi.org/10.5863/1551-6776-25.5.401
8. Billnitzer A, Jankovic J. Current management of tics and Tourette syndrome: Behavioral, pharmacologic, and surgical treatments. Neurotherapeutics. 2020;17(4):1681–93. DOI: https://doi.org/10.1007/s13311-020-00914-6
9. Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757–77. DOI: https://doi.org/10.2147/TCRM.S117321
10. Hartmann A, Andrén P, Atkinson-Clément C, Czernecki V, Delorme C, Monique Debes NM, et al. Tourette syndrome research highlights from 2022. F1000Res. 2023;12:826. DOI: https://doi.org/10.12688/f1000research.135702.2
11. Piscura MK, Henderson-Redmond AN, Barnes RC, Mitra S, Guindon J, Morgan DJ. Mechanisms of cannabinoid tolerance. Biochem Pharmacol. 2023;1(214):115665. DOI: https://doi.org/10.1016/j.bcp.2023.115665
12. Parrella NF, Hill AT, Enticott PG, Barhoun P, Bower IS, Ford TC. A systematic review of cannabidiol trials in neurodevelopmental disorders. Pharmacol Biochem Behav. 2023;230:173607. DOI: https://doi.org/10.1016/j.pbb.2023.173607
13. Müller-Vahl KR, Schneider U, Prevedel H, Theloe K, Kolbe H, Daldrup T, et al. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: A 6-week randomized trial. J Clin Psychiatry. 2003;64(4):459–65. DOI: https://doi.org/10.4088/JCP.v64n0417
14. Thaler A, Arad S, Schleider LBL, Knaani J, Taichman T, Giladi N, et al. Single center experience with medical cannabis in Gilles de la Tourette syndrome. Parkinsonism Relat Disord. 2019;61:211–3. DOI: https://doi.org/10.1016/j.parkreldis.2018.10.004
15. Greydanus D, Tullio J. Tourette’s disorder in children and adolescents. Transl Pediatr. 2019;9(4):263-8.
16. Szejko N, Kaczmarek-Skamira E, Kłos K, Chrostek A. Tics and psychiatric comorbidities in Tourette syndrome—a review of pharmacological and non-pharmacological therapies. Int J Mol Sci. 2022;23(22):13778.
17. Fernández-Ruiz J. The endocannabinoid system as a target for the treatment of motor dysfunction. Br J Pharmacol. 2009;156:1029–40. doi: 10.1111/j.1476-5381.2008.00088.x DOI: https://doi.org/10.1111/j.1476-5381.2008.00088.x
18. Müller-Vahl KR, Bindila L, Schneider U, Theloe K, Hinz B, Lutz B. Increased anandamide levels in the cerebrospinal fluid of patients with Tourette’s syndrome. Transl Psychiatry. 2020;10(1):159.
19. Lu D, Mackie K. Review of the involvement of the endocannabinoid system in basal ganglia function. Brain Res Bull. 2021;173:331–40.
20. Centonze D, Battista N, Rossi S, Mercuri NB, Finazzi-Agrò A, Bernardi G, et al. A critical interaction between dopamine D2 receptors and endocannabinoids mediates the effects of cocaine on striatal gabaergic transmission. Neuropsychopharmacology. 2004;29:1488–97. doi: 10.1038/sj.npp.1300458. DOI: https://doi.org/10.1038/sj.npp.1300458
21. García C, Palomo-Garo C, Gómez-Gálvez Y, Fernández-Ruiz J. Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia. Br J Pharmacol. 2016;173:2069–79. doi: 10.1111/bph.13215. DOI: https://doi.org/10.1111/bph.13215
22. Müller-Vahl KR, Prevedel H, Schneider U, Theloe K, Kolbe H, Emrich HM. Treatment of Tourette syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized, controlled crossover trial. Pharmacopsychiatry. 2002;35(2):57–61. DOI: https://doi.org/10.1055/s-2002-25028
23. Jakubovski E, Müller-Vahl K. Speechlessness in Gilles de la Tourette syndrome: cannabis-based medicines improve severe vocal blocking tics in two patients. Int J Mol Sci. 2017;18(8):1779. DOI: https://doi.org/10.3390/ijms18081739
24. Trainor K, Satija A, Cavanna AE. Cannabis use in Tourette syndrome: an update. Int Rev Neurobiol. 2016;131:219–30.
Publicado
Declaração de Disponibilidade de Dados
Os dados não estão disponibilizados.
Edição
Seção
Categorias
Licença
Copyright (c) 2025 Brazilian Journal of Medical and Health Sciences
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
